143 related articles for article (PubMed ID: 30046225)
1. Effectiveness and safety of different amifostine regimens: Preliminary results of a phase II multicenter randomized controlled trial.
Chang H; Yi W; Wang X; Tao Y; Yang X; Chen C; Zhang W; Zhou S; Liu S; Li X; Ding S; Li J; Li G; Shao X; Liu Y; Song W; Xia Y
Chin J Cancer Res; 2018 Jun; 30(3):307-314. PubMed ID: 30046225
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
7. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.
Tang C; Wu F; Wang R; Lu H; Li G; Liu M; Zhu H; Zhu J; Zhang Y; Hu K
Am J Cancer Res; 2016; 6(9):2064-2075. PubMed ID: 27725911
[TBL] [Abstract][Full Text] [Related]
8. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
9. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.
Peng G; Wang T; Yang KY; Zhang S; Zhang T; Li Q; Han J; Wu G
Radiother Oncol; 2012 Sep; 104(3):286-93. PubMed ID: 22995588
[TBL] [Abstract][Full Text] [Related]
11. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
[TBL] [Abstract][Full Text] [Related]
12. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ
JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
[TBL] [Abstract][Full Text] [Related]
14. Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy Does Not Improve Treatment Outcomes for Stage II Nasopharyngeal Carcinoma: A Phase 2 Multicenter Clinical Trial.
Huang X; Chen X; Zhao C; Wang J; Wang K; Wang L; Miao J; Cao C; Jin T; Zhang Y; Qu Y; Chen X; Liu Q; Zhang S; Zhang J; Luo J; Xiao J; Xu G; Gao L; Yi J
Front Oncol; 2020; 10():1314. PubMed ID: 32850414
[No Abstract] [Full Text] [Related]
15. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
16. [Concurrent chemotherapy with different dose regimens of cisplatin for nasopharyngeal carcinoma using intensity-modulated radiation therapy: a phase II prospective randomized controlled trial].
Liu S; Han F; Chen C; Zeng L; Sun X; Lu T
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):778-82. PubMed ID: 25567311
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
[TBL] [Abstract][Full Text] [Related]
18. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.
Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH
Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
